Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. develops and commercializes medical device products for active healing, pain treatment, musculoskeletal care and surgical applications. The company organizes its portfolio around Pain Treatments, Restorative Therapies and Surgical Solutions, including products such as peripheral nerve stimulation devices, bone graft substitutes, ultrasonics, hyaluronic acid injections and ultrasound-based fracture healing therapies.
Recurring Bioventus news covers quarterly and annual results, financial guidance, revenue trends across its product areas and geographic markets, cash flow and margin performance, healthcare conference presentations, portfolio updates and regulatory developments affecting products such as Peripheral Nerve Stimulation offerings.
Bioventus Inc. (Nasdaq: BVS) reported strong first-quarter financial results with a revenue increase of 8.7% and organic growth of 15.3%. The company raised its full-year 2024 financial guidance, reflecting enhanced revenue growth and strategic execution. Gross margin expanded significantly, and adjusted EBITDA from continuing operations increased by 33.5%. Bioventus achieved key milestones, including revenue growth in Pain Treatments and Surgical Solutions, liquidity enhancement, and EU MDR Certification for Exogen Bone Stimulation System. The company now expects net sales of $535 million to $550 million, adjusted EBITDA of $94 million to $99 million, and non-GAAP EPS of $0.25 to $0.33 for 2024.
Bioventus Inc. (Nasdaq: BVS) will release its financial results for the first quarter of fiscal year 2024 on May 7, 2024. The management will conduct a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update. Participants can join the call by dialing 1-833-636-0497 or accessing the live webcast on the company's website. The webcast will be available for replay until May 6, 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.